+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Matrix metalloproteinases in neuroinflammation



Matrix metalloproteinases in neuroinflammation



Glia 39(3): 279-291



Matrix metalloproteinases (MMPs) are a gene family of neutral proteases that are important in normal development, wound healing, and a wide variety of pathological processes, including the spread of metastatic cancer cells, arthritic destruction of joints, atherosclerosis, and neuroinflammation. In the central nervous system (CNS), MMPs have been shown to degrade components of the basal lamina, leading to disruption of the blood-brain barrier (BBB), and to contribute to the neuroinflammatory response in many neurological diseases. Brain cells express both constitutive and inducible MMPs in response to cellular stress. MMPs are tightly regulated to avoid unwanted proteolysis. Secreted as inactive enzymes, the MMPs require activation by other proteases and free radicals. The MMPs are part of a larger class of metalloproteinases (MPs), which includes the recently discovered ADAMs (a disintegrin and metalloproteinase domain) and ADAMTS (a disintegrin and metalloproteinase thrombospondin) families. MPs have complex roles at the cell surface and within the extracellular matrix. At the cell surface, they act as sheddases, releasing growth factors, death receptors, and death-inducing ligands, making them important in cell survival and death. Tissue inhibitors of metalloproteinases (TIMPs) are endogenous inhibitors that regulate the activity of the MMPs. Synthetic inhibitors have been developed for the treatment of arthritis and cancer. These hydroxymate-based compounds have been shown to reduce injury in experimental allergic encephalomyelitis (EAE), experimental allergic neuritis (EAN), cerebral ischemia, intracerebral hemorrhage, and viral and bacterial infections. MPs have both beneficial and detrimental roles; understanding their expression in various CNS insults will allow for the use of MMP inhibitors in the treatment of neurological disorders.

(PDF emailed within 0-6 h: $19.90)

Accession: 046631376

Download citation: RISBibTeXText

PMID: 12203394

DOI: 10.1002/glia.10108


Related references

Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience 158(3): 983-994, 2008

Matrix metalloproteinases in neuroinflammation and cerebral ischemia. Ernst Schering Research Foundation Workshop: 1-16, 2004

Matrix metalloproteinases and neuroinflammation in multiple sclerosis. Neuroscientist 8(6): 586-595, 2002

Marine pharmacology: therapeutic targeting of matrix metalloproteinases in neuroinflammation. Drug Discovery Today (): -, 2016

The role of microglia and matrix metalloproteinases involvement in neuroinflammation and gliomas. Clinical & Developmental Immunology 2013: 914104-914104, 2014

β-Lapachone suppresses neuroinflammation by modulating the expression of cytokines and matrix metalloproteinases in activated microglia. Journal of Neuroinflammation 12(): 133-133, 2016

Effect of simvastatin on serum matrix metalloproteinases-1, matrix metalloproteinases-9, tissue inhibitor of metalloproteinases-1, high sensitive C-reactive protein levels in patients of acute coronary syndrome in serum normocholesterolemia and hypercholesterolemia level. Zhonghua Xinxueguanbing Zazhi 32(2): 109-113, February 19, 2004

Distribution pattern of matrix metalloproteinases 1, 2, 3, and 9, tissue inhibitors of matrix metalloproteinases 1 and 2, and alpha 2-macroglobulin in cases of generalized AA- and AL amyloidosis. Virchows Archiv 437(5): 521-527, 2001

Hydrocortisone affects the expression of matrix metalloproteinases (MMP-1, -2, -3, -7, and -11) and tissue inhibitor of matrix metalloproteinases (TIMP-1) in human gingival fibroblasts. Journal of Periodontology 78(7): 1309-1315, 2007

Expression of bone morphogenetic proteins, matrix metalloproteinases and inhibitors of matrix metalloproteinases in lung cancers and their prognostic significance. Postepy Biochemii 54(1): 82-90, 2008

Matrix metalloproteinases, tissue inhibitors of matrix metalloproteinases and angiogenic cytokines in peripheral blood of patients with thyroid cancer. Thyroid 12(8): 655-662, 2002

Differential release of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in patients following alcohol induced myocardial infarction. Circulation 104(17 Supplement): II 305, October 23, 2001

Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of the matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. Journal of Pathology 182(3): 347-355, 1997

Effects of reduced β2-glycoprotein I on the expression of aortic matrix metalloproteinases and tissue inhibitor matrix metalloproteinases in diabetic mice. Bmc Cardiovascular Disorders 14(): 114-114, 2015

Expression of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases in mesothelial cells and their regulation by transforming growth factor-beta1. Wound Repair and Regeneration 7(6): 477-485, 2000